Insulet Archives - Page 6 of 9 - Medical Design Sourcing

Dexcom quashes talk of Insulet merger, says discussions are not ongoing

Dexcom (Nasdaq:DXCM) has today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD).

Last week, reports circulated saying talks over a potential acquisition were ongoing with an agreement between the two diabetes technology developers on the horizon in the coming weeks.

On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 per share as the market opened today. Conversely, PODD shares sank 11% to $209.65.

Get the full story at our sister site, Drug Delivery Business News.

Report: Dexcom in talks to acquire Insulet

Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD).

Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous because the information is private and both companies declined to offer comment, the news outlet said.

Get the full story at our sister site, Drug Delivery Business News.

Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change

The future for Insulet (Nasdaq:PODD) has a much different look on some level than it did about a week ago.

A massive shake-up at the executive level came on May 5 when Shacey Petrovic announced that she would step down as the company’s president and CEO for personal reasons.

Petrovic will stay on as a board member at the Acton, Massachusetts-based automated insulin delivery system developer, and will assume an advisory role to support the leadership transition to former ResMed President of Sleep and Respiratory Care Jim Hollingshead, who will succeed her.

While the executive makeup will change come June 1, Insulet’s efforts to innovate in the diabetes space won’t be halted, as the company will continue to plug along under new leadership, EVP of Innovation and Strategy Eric Benjamin said during a keynote event at DeviceTalks Boston.

Get the full story at our sister site, Drug Delivery Business News.

Shacey Petrovic to step down as Insulet CEO, ResMed exec Jim Hollingshead to take role

Insulet (Nasdaq:PODD) announced today that President and CEO Shacey Petrovic will step down for personal family reasons.

Petrovic will step down from her position effective June 1, 2022, but will continue to serve on the company’s board. She will also serve as an advisor to the company through May 2023 to support the leadership transition to Jim Hollingshead, who will succeed Petrovic effective June 1.

Hollingshead has served as an independent member of Insulet’s board of directors since 2019 and currently serves as president of sleep and respiratory care at ResMed.

Get the full story at our sister site, Drug Delivery Business News.

Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]Insulet (Nasdaq:PODD) shares were down after hours despite first-quarter results that topped the consensus forecast.

The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022, for a big bottom-line gain from breakeven this time a year ago on sales growth of 17.1%.

Insulet, the maker of the Omnipod 5 automated insulin delivery system, which garnered FDA clearance during the quarter, saw its EPS come in 17¢ ahead of projections on Wall Street, where analysts were looking for sales of $288.2 million.

Get the full story at our sister site, Drug Delivery Business News.

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Get the full story at our sister site, Drug Delivery Business News.

Insulet announces study data for Omnipod 5 for type 1, type 2 diabetes

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes.

Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain.

Get the full story at our sister site, Drug Delivery Business News.

How Insulet created its next-gen Omnipod 5

Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January.

Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Users can use a dedicated handheld controller or control the system with a secure app on their smartphone, marking another first.

Join us at DeviceTalks Boston on May 10-11, 2022, for a keynote interview with Insulet CEO Shacey Petrovic to learn about the story behind the game-changing Omnipod 5.

DeviceTalks Boston will unite medtech’s most innovative professionals and help attendees clear troublesome bottlenecks in the critical stages of medical device development. We will explore the trends and technology that are shaping the future of the medical device…

How Insulet created its next-gen Omnipod 5

Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January.

Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Users can use a dedicated handheld controller or control the system with a secure app on their smartphone, marking another first.

Join us at DeviceTalks Boston on May 10-11, 2022, for a keynote interview with Insulet CEO Shacey Petrovic to learn about the story behind the game-changing Omnipod 5.

DeviceTalks Boston will unite medtech’s most innovative professionals and help attendees clear troublesome bottlenecks in the critical stages of medical device development. We will explore the trends and technology that are shaping the future of the medical device…

Diabetes tech is off to a hot start in 2022

Diabetes technology developers have high hopes for the year ahead, some of which have already come to fruition.

Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.

Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.

Get the full story at our sister site, Drug Delivery Business News.

Diabetes tech is off to a hot start in 2022

Diabetes technology developers have high hopes for the year ahead, some of which have already come to fruition.

Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.

Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.

Get the full story at our sister site, Drug Delivery Business News.

Insulet features on Nintendo’s ‘Animal Crossing’ video game to promote inclusivity for diabetes community

Animal Crossing characters visiting Omnipod Bay. [Image from Insulet/Nintendo]Insulet (NSDQ:PODD) announced today that its Omnipod brand of products will feature on Nintendo’s Animal Crossing video game.

Acton, Massachusetts-based Insulet aims to promote representation and inclusion for the diabetes community through an activation on Animal Crossing: New Horizons.

Get the full story at our sister site, Drug Delivery Business News.